Endiatx’s swallowable robotic pill, PillBot, is entering clinical trials and preparing for FDA review, aiming for a commercial launch by early 2026. PillBot, equipped with cameras and sensors, offers a non-invasive alternative to traditional endoscopy by providing real-time imagery of the gastrointestinal tract. The company, which has raised $7 million, envisions AI integration to eventually allow autonomous navigation and diagnosis, potentially revolutionizing gastroenterology by making advanced diagnostic procedures more accessible and cost-effective.
Keep Reading
Add A Comment